Advertisement
Advertisement
U.S. markets close in 5 hours 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Neoleukin Therapeutics, Inc. (NLTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9672-0.0528 (-5.18%)
As of 10:07AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close1.0200
Open1.0400
Bid0.9801 x 900
Ask0.9899 x 900
Day's Range0.9672 - 1.0499
52 Week Range0.7950 - 9.7500
Volume27,005
Avg. Volume380,535
Market Cap41.11M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-1.1090
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NLTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Neoleukin Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/27/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • GlobeNewswire

    Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)

    SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory soli

  • GlobeNewswire

    Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

    SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escala

  • GlobeNewswire

    Neoleukin Therapeutics to Present at Upcoming Investor Conferences

    SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows: BofA Securities 2022 Healthcare Conference – Las Vegas, NV Fireside chatWednesday May 11, 2022, at 1:20 p.m. Pacific H.C. Wa

Advertisement
Advertisement